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The transcriptional coactivator p300 functions as a histone acetyltransferase and a scaffold for tran- 
scription factors. We investigated the effect of cAMP signalling on p300 expression. The activation of 
cAMP signalling by the expression of constitutively active Gas or by treatment with isoproterenol 
decreased the p300 protein expression in lung cancer cells. Isoproterenol promoted the ubiquitina- 
tion and subsequent proteasomal degradation of p300 in an Epac-depen dent manner. Epac pro- 
moted p300 degradation by inhibiting the activity of p38 MAPK. It is concluded that cAMP 
signalling decreases the level of the p300 protein by promotin g its ubiquitin–proteasome dependen t
degradation, which is mediated by Epac and p38 MAPK, in lung cancer cells. 
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. 1. Introduction cAMP binds to and activates three major effector molecule s to reg- The transcriptional coactivat or p300 was identiﬁed through its 
binding to the adenovirus early-region 1A protein, and it functions 
as an acetyltransf erase for histones and non-histo ne proteins such 
as p53, MDM2, and cyclins [1]. p300 also acts as a scaffold for tran- 
scription factors to facilitate chromatin remodelling and to activate 
gene transcriptio n [2]. As a transcriptional co-activator, p300 binds 
to transcriptio n factors such as TFIIB and TFIID. Thus, p300 is 
involved in the regulation of many biological functions, including 
cell proliferation, differentiation , apoptosis, and senescence. There- 
fore, targeting p300 is considered as a promising therapeutic strat- 
egy for many diseases, including cancer [3]. The activity of p300 is 
regulated by various mechanisms, including acetylation, phos- 
phorylation, proteaso mal degradation, and cellular distribut ion [4].
Cyclic AMP (cAMP) is a second messeng er that is formed by 
adenylate cyclases. The activity of adenylate cyclase is regulated 
by the heterotrimeric GTP-binding proteins (G proteins). G proteins 
are activated by various G protein coupled receptors (GPCRs) in the 
plasma membrane when they are bound by their speciﬁc ligands. ulate cellular responses: the cAMP-de pendent protein kinase A
(PKA), nucleotide- gated ion channels and exchange protein acti- 
vated by cAMP (Epac). PKA phosphoryla tes many target proteins 
to regulate cell metaboli sm and gene expression, while Epac func- 
tions as a guanine nucleotid e exchange factor for Rap, which is a
small G protein, to regulate cell growth, differentiation , and secre- 
tion [5]. The cAMP signalling system is thought to control gene 
expression through epigenetic regulation mechanism s such as his- 
tone acetylation and phosphorylatio n. Thus, we hypothes ised that 
the cAMP signalling system may regulate p300 to control gene 
expression epigenetical ly. We investiga ted the effect of cAMP sig- 
nalling on p300 expression and the underlying molecular mecha- 
nism. We found that cAMP signalling decrease s the levels of p300 
by promoting its Epac- and p38 MAPK-mediate d degradat ion. 
2. Materials and methods 
2.1. Cell culture and reagents 
Human non-sma ll cell lung cancer cells (H1299 and A549) were 
purchase d from the Korean Cell Line Bank (Seoul, Korea). H1299 
cells were cultured in Dulbecco’s Modiﬁed Eagle’s medium, and 
A549 cells were cultured in RPMI1640. The media contained 10% 
foetal bovine serum (Welgene, Daegu, Korea), 100 units/ml penicil- 
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Fig. 1. cAMP signalling decreased the levels of the p300 protein in human lung 
cancer cells. (A) The effect of Gas on the level of p300 protein in H1299 cells. L and S
indicate the long and the short form of the Gas protein, respectively. (B) The effect 
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CO2 at 37 C.
Isoproteren ol, cycloheximide , H89, penicillin, streptomy cin, di- 
methyl sulfoxide , 6-Bnz-cAMP sodium salt (6-Bnz-cAMP), and bre- 
feldin A were purchased from Sigma–Aldrich (St. Louis, MO, USA).
MG132 and SB20358 0 were purchase d from Cayman Chemical (La
Jolla, CA, USA), and 8-pCPT-2 0-O-Me-cAMP (8-pCPT-cAMP) was pur- 
chased from Biological Life Science Institute (Bremen, Germany).
2.2. Quantitative reverse transcription polymerase chain reaction 
(qPCR)
qPCR was performed using a C1000 thermal cycler (BioRad,
Hercules, CA, USA) as previously described [6]. The primers used 
for p300 were 50-AGCCAAA GAAAAAGATTTTC A-3 0 (forward) and 50-
ACATCACTGGG TCAATTTCT T-3 0 (reverse). After 40 cycles of PCR, the 
average threshold cycle (Ct) value for p300 was normalised to that 
of GAPDH. 
2.3. Expression plasmid and transient transfectio n
A constituti vely active EE-tagge d mutant of the long form of 
Gas (GasQ227L and GasQL) in the pcDNA3 vector was purchased 
from Missouri S&T cDNA Resource Center (Rolla, MO, USA). The 
plasmids expressing a short hairpin RNA targeting Epac1 (shEpac1)
and a control shRNA were purchase d from Sigma–Aldrich. The 
dominant negative form of PKA was a gift from Dr. G. Stanley 
McKnight (University of Washington, USA). The dominant negative 
p38 (p38AF) mutant was a gift from Dr. Dongeun Park (Seoul Na- 
tional University, Korea), and the constitutively active MKK3 and 
MKK6 were provided by Dr. Lynn Taylor (Colorado State Univer- 
sity, USA). The plasmids were expressed by a transient transfection 
using the calcium phosphate method. 
2.4. Western blot analysis 
Western blotting was performed as previously described [7].
Antibodies against p300, ubiquitin , Epac, and MEK-3/6 were pur- 
chased from Santa Cruz Biotechnolo gy (Santa Cruz, CA, USA), and 
antibodies against pCREB, pp44/p42 MAPK, pSAPK/JNK, pp38 
MAPK, pAkt, p44/p42 MAPK, SAPK/JNK, p38 MAPK, Akt, and 
pMKK3/MKK6 were purchased from Cell Signaling Technolo gy 
(Beverly, MA, USA). An antibody against EE was purchased from 
Covance (Princeton, NJ, USA), and an antibody against b-actin
was purchased from Sigma–Aldrich. Proteins were visualised using 
an ECL solution (Thermo Fisher Scientiﬁc; Waltham, MA, USA), and 
protein blot images were recorded with the LAS-3000 luminescen t
image analyser (Fuji; Tokyo, Japan). Protein expression was quan- 
tiﬁed using Multi Gauge v.2.3 software and was presente d as a ra- 
tio to the appropriate control. 
2.5. Data analysis 
All experiments were repeated at least three times indepen- 
dently, and the data are presented as the means ± standard errors. 
The non-parame tric Mann–Whitney U test was used to analyse the 
mean values, and a P value of less than 0.05 was considered stati- 
cally signiﬁcant.of isoproterenol on the level of p300 protein in H1299 cells. (C) The effect of 
isoproterenol on the level of p300 protein in A549 cells. (D) The effect of cAMP 
signalling on the level of p300 mRNA. H1299 cells were transfected with EE-tagged 
GasQL or the pcDNA3 vector (V), and the levels of p300 protein and mRNA were 
analysed after 24 h of incubation (A & D). H1299 and A549 cells were treated with 
1 lM isoproterenol (IPO) for 30 min or the indicated duration prior to the analysis 
of protein and mRNA levels. Protein levels were analysed by electrophoresis on 5% 
polyacrylamide gel and Western blotting with b-actin as a loading control. The 
mRNA expression was analysed by qPCR. Asterisks (⁄) on the histograms indicate a
statistically signiﬁcant difference from the respective control. 3. Results 
3.1. cAMP signalling is associated with lower levels of p300 
To examine the effect of cAMP signalling on p300 levels, a con- 
stitutively active form of Gas (GasQL) was transiently transfected into H1299 human non-small cell lung cancer cells. The expression 
of the transfected GasQL was conﬁrmed by Western blot analysis 
using antibodie s speciﬁc to Gas and the EE tag. The expression of 
GasQL signiﬁcantly decreased the level of the p300 protein in the 
H1299 cells (Fig. 1A) but upregulated the expression of the p300 
mRNA (Fig. 1D). Moreover, treatment with isoproterenol, which 
is an agonist of Gas-coupled b-adrenergic receptors, transiently 
decrease d the level of the p300 protein, achieving the minimal le- 
vel at 30 min after treatment, and it also decreased the p300 mRNA 
level in the H1299 cells (Fig. 1B and D). A549 lung cancer cells trea- 
ted with isoproter enol also exhibited decreases in the levels of 
both p300 mRNA and protein, with the lowest levels observed at 
90 min post treatment (Fig. 1C and D). The above results indicate 
that cAMP signalling decrease d the p300 protein level in human 
lung cancer cells. 
3.2. cAMP signalling promoted the ubiquitin/protea some-dependen t
degradatio n of the p300 protein 
To study how cAMP signalling decrease d the accumulation 
of the p300 protein, we analysed the degradation rate of the 
M.-J. Jeong et al. / FEBS Letters 587 (2013) 1373–1378 1375protein after blocking protein biosynthesis by treatment with 
cycloheximi de. Treatment with isoproterenol increased the deg- 
radation rate of the p300 protein (Fig. 2A). Then, to assess 
whether the degradat ion of p300 was proteasome dependent, 
the effect of a proteasome inhibitor, MG-132, was analysed. 
Pretreatment with MG132 completely blocked the degradation 
of the p300 protein in the presence or absence of isoproterenol 
(Fig. 2B). Because protein ubiquitin ation is typically required 
for its proteasomal degradation, the ubiquitination of the p300 
protein was assessed. Isoproteren ol treatment increased the 
amount of the ubiquitinated protein in the p300 immunopreci p- 
itates (Fig. 2C). These results indicate that cAMP signalling de- 
creased the p300 protein levels by promoting its ubiquitin –
proteasome depende nt degradat ion. - 15 30 60 120
Control
p300
pCREB
β-Actin
Time after trea
-
0
0.5
1
1.5
0 30 60
p3
00
 p
ro
te
in
 (r
at
io
)
A
B
p300
p-CREB
β-Actin
0
1
2
3
p3
00
 p
ro
te
in
 (r
at
io
)
IPO - + - - + +
MG132 - - - + - +
CHX - - + + + +
*
*
**
**
C
IB
IB
Fig. 2. Isoproterenol promoted the ubiquitin/proteasome-dependent degradation of the p
cells were pretreated with 10 lg/ml cycloheximide (CHX) for 10 min and then treated w
blocked the isoproterenol-promoted degradation of the p300 protein. H1299 cells wer
30 min, and then with 1 lM isoproterenol for a further 30 min. Asterisks (⁄) indicate a s
asterisks (⁄⁄) indicate a statistically signiﬁcant difference from the isoproterenol-treated
were treated with 1 lM isoproterenol for 30 min. The whole cell lysate (WCL, 400 lg p
centrifugation. The precleared lysate was incubated with an anti-p300 antibody (1 lg) or
for 3 h. The resulting immunoprecipitates were washed 3 times and then analysed by W3.3. cAMP signalling promoted the degradation of the p300 protein in 
an Epac1-dep endent pathway 
To further understand how the cAMP signalling system pro- 
moted the degradat ion of the p300 protein, the role of PKA was 
analysed. Treatment with a selective PKA inhibitor, H89, decreased 
the levels of p300 protein, and co-treatment with H89 and isopro- 
terenol did not block the p300-decrea sing effect of isoproterenol 
(Fig. 3A). The expression of a dominan t negative PKA also 
decrease d the basal p300 protein level and did not block the 
p300-dec reasing effect of isoproterenol (Supplement ary Fig. 1). In 
addition, treatment with a PKA selective activator, 6-Bnz-cAMP, 
slightly increased the basal p300 protein level, and co-treatment 
with 6-Bnz-cA MP and isoproterenol also increased the p300 IPO
tment (min)
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Fig. 3. Isoproterenol promoted the degradation of p300 by activating Epac1. (A) The 
inhibition of PKA by H89 did not block the isoproterenol-induced decrease in p300 
levels. H1299 cells were pretreated with 40 lM H89 for 30 min before treatment 
with 1 lM isoproterenol. (B) The activation of PKA by 6-Bnz-cAMP did not decrease 
the levels of p300. (C) The activation of Epac by the 8-pCPT-cAMP decreased the 
levels of p300. (D) The shRNA-mediated knockdown of Epac1 blocked the 
isoproterenol-induced decrease in p300 levels. H1299 cells were transfected with 
shEpac1 or a scrambled shRNA (S) and incubated for 24 h prior to the isoproterenol 
treatment. H1299 cells were treated with 1 lM isoproterenol, 10 lM 6-BNZ-cAMP, 
or 20 lM 8-pCPT-cAMP for 30 min prior to the analysis. Asterisks (⁄) indicate a
statistically signiﬁcant difference from the vehicle-treated control, and double 
asterisks (⁄⁄) indicate a statistically signiﬁcant difference from the isoproterenol- 
treated control. 
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(Fig. 3B). These results indicate that the degradation of the p300 
protein is promoted by cAMP signalling in a PKA-indep endent 
manner, even though PKA increases the basal level of p300 protein. 
Therefore, the role of Epac, another cAMP effector, in the degrada- 
tion of p300 was studied. Treatment with 8-pCPT-c AMP, an Epac- 
selective activator, decrease d the p300 protein levels to a degree 
similar to that of isoproterenol treatment (Fig. 3C), and the co- 
treatment of isoproterenol with brefeldin A, an Epac inhibitor, 
completely blocked the effect of isoproter enol and markedly 
increased the p300 protein levels (Supplementary Fig. 2).
Knockdown of Epac1 using an Epac1-speciﬁc shRNA also blocked 
the isoproter enol-induced decrease in p300 protein levels 
(Fig. 3D). These results indicate that cAMP signalling promotes 
the degradation of the p300 protein through an Epac1-m ediated 
pathway.3.4. Epac1 promoted the degradation of the p300 protein by inhibiting 
p38 activity 
To probe how Epac1 promoted the degradat ion of the p300 pro- 
tein, the role of the mitogen activated protein kinases (MAPKs) was 
analysed; MAPKs can be activated by Epac1 and may be involved in 
the regulation of the p300 protein. Treatment with isoproter enol or 
8-pCPT-c AMP decreased the phosphorylatio n of ERK, JNK, p38 
MAPK and AKT (Supplement ary Fig. 3). Treatment with 8-pCPT- 
cAMP resulted in a greater inhibition of the activation of p38 than 
did treatment with isoproterenol. Thus, the effect of p38 inhibition 
on p300 accumulation was examine d further. The inhibition of p38 
by treatment with a speciﬁc inhibitor, SB203580, or by the expres- 
sion of the dominant negative p38 decreased the levels of p300 
protein accumulation (Fig. 4A and B). Isoproterenol inhibited the 
basal phosphoryla tion of MKK3 and MKK6, the upstream kinases 
that activate p38 (Fig. 4C and D). The activation of p38 signalling 
by the expression of constitutivel y active MKK3 or MKK6 increased 
p300 levels and blocked the isoproter enol-induced abrogation of 
p300 (Fig. 4C and D). These results indicate that Epac promoted 
the degradat ion of the p300 protein by inhibiting p38 activity. 
4. Discussion 
The potential role of cAMP signalling in regulatin g the levels of 
p300 in lung cancer cells and its underlyin g molecular mechanis m
is of great interest. We found that cAMP signalling decreases p300 
protein levels by promoting the ubiquitin/prote asome-dependen t
degradat ion of p300 through an Epac1-mediate d inhibition of the 
p38 MAPK activity in lung cancer cells. This conclusion is based 
on several complementar y results. First, the activation of cAMP sig- 
nalling decreased the levels of p300 protein. Second, isoproter enol 
treatment enhanced the ubiquitination of p300 and promote d its 
proteaso mal degradat ion. Third, the activation of Epac decreased 
p300 levels, but the inhibition of Epac1 blocked the isoproter e- 
nol-induced decrease in p300 protein levels. Finally, isoproter enol 
inhibited p38 kinase activity, and the activation of p38 signalling 
blocked the isoproterenol -induced decreased in p300 protein 
accumulati on. 
The conclusion that cAMP signalling inhibits the accumulation 
of p300 was based on the ﬁnding that the activation of cAMP sig- 
nalling by the expression of the constitutivel y active Gas or by 
treatment with isoproter enol decreased the levels of p300 protein. 
This study demonstrat ed that cAMP signalling lowered the p300 
protein levels in the H1299 and A549 lung cancer cells. The p300 
protein was found to be degraded by the proteaso me in rat cardio- 
myocyte s treated with doxorubicin [8], and the proteasomal degra- 
dation of p300 has been reported to be regulated by several 
molecule s, including retinoic acid [9], platelet-derive d growth fac- 
tor (PDGF) [10], myostatin [11], and the E6 protein of the beta pap- 
illomavirus es [12]. Signalling molecules including ras, 
phosphat idylinositol 3-kinase, PTEN, and Akt were also found to 
be involved in the regulation of p300 protein degradat ion [11].
However , no previous reports have shown the regulatio n of p300 
degradat ion by cAMP signalling. To the best of our knowledge, this 
paper presents the ﬁrst evidence that the cAMP signalling system 
can regulate the proteaso mal degradat ion of the p300 protein. This 
ﬁnding suggests that the accumulation of p300 may be regulated 
by the cAMP signalling activity. 
We found that the cAMP signalling system decreases p300 
protein levels by promoting the ubiquitin/prote asome-dependen t
degradat ion of p300. This conclusion is supported by the follow- 
ing results: isoproterenol stimulated the degradation of p300 
protein in cycloheximide -pretreated cells, proteasoma l inhibition 
blocked the isoproterenol-sti mulated degradat ion of p300, and 
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Fig. 4. Isoproterenol promoted the degradation of p300 by inhibiting p38. (A) The 
inhibition of p38 by SB203580 decreased the accumulation of the p300 protein. (B)
The inhibition of p38 via a dominant negative p38 (p38AF) decreased the 
accumulation of the p300 protein. (C) The activation of p38 by a constitutively 
active MKK6 (MKK6(glu)) blocked the isoproterenol-induced abrogation of p300. 
(D) The activation of p38 by constitutively active MKK3 (caMKK3) blocked the 
isoproterenol-induced decrease in p300 protein levels. H1299 cells were transfec- 
ted with the p38AF, caMKK3, or MKK6(glu) plasmids and then incubated for 24 h
before treatment with isoproterenol. H1299 cells were treated with 1 lM isopro- 
terenol, 20 lM 8-pCPT-cAMP, or 20 lM SB203580 for 30 min prior to analysis. 
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are consistent with previous reports showing that the p300 protein 
was degraded by the ubiquitin/prote asome system [8,9,13]. Our 
ﬁndings are also compatible with data showing that cAMP signalling 
regulates the ubiquitin /proteasome-dep endent degradat ion of 
many proteins, such as the regulatory subunits of PKA, cyclin D1 
and D3, glucocorticoid receptor-i nteracting protein and XRCC1 
[14–17]. Recently , BRMS1 was reported to function as an E3 ligase 
for p300 [18]. Thus, the role of BRMS1 in cAMP signalling-induce d
p300 degradation needs to be examined in a future study. In further experiments to study how cAMP signalling promoted 
the proteasoma l degradation of the p300 protein, we found that 
Epac promotes the degradation of p300. Treatment with the Epac- 
selective activator 8-pCPT-c AMP decrease d the p300 levels, and 
the inhibition of Epac1 by a speciﬁc inhibitor or an shRNA targeting 
Epac1 blocked the isoproterenol-ind uced down-regul ation of p300. 
In contrast, PKA was not found to affect the cAMP signalling -
mediated decrease in p300 levels. The PKA-selective activator 6- 
Benz-cAMP did not decrease the levels of the p300 protein, and 
the inhibition of PKA by a speciﬁc inhibitor or a dominant negative 
PKA did not block the isoproterenol-me diated decrease in p300 
levels. Epac is activated by binding to cAMP, which induces confor- 
mational changes and abolishes its autoinhibi tion. Activated Epac 
functions as guanine nucleotide exchange factors (GEF) for the 
Rap proteins, leading to Rap activation [5]. Thus, the Rap proteins 
ar e su gge st ed to me di at e th e p30 0 deg rad at ion dow nst re am of Epa c. 
A study examining the signalling molecules downstream of 
Epac found that p38 MAPK was able to mediate the cAMP signal- 
ling-indu ced decrease of p300 protein levels. Cyclic AMP signalling 
inhibited p38 activation, the inhibition of p38 by a speciﬁc inhibi- 
tor or a dominant negative mutant p38 decreased the p300 protein 
levels, and the activation of p38 by upstream kinases blocked the 
cAMP signalling -induced degradation of the p300 protein. p38 
was reported to phosphorylate p300 and trigger its degradation 
in cardiomyocy tes and in cancer cell lines [19,20]. However, our 
data showed that the inhibition of the p38 activity by cAMP signal- 
ling triggered the degradation of p300, suggesting that p38 might 
regulate the E3 ligase differently or might regulate another E3 li- 
gase responsible for the p300 ubiquitinati on. In addition, p38 
was found to be inhibited by cAMP signalling. However, Epac1 
was reported to activate p38 in a PKC d- or a Rap1-dep endent path- 
way [21,22]. This discrepancy could result from a cell type-speciﬁc
regulatio n of the signalling molecule s upstream and downstre am 
of p38 in each system, but the mechanism underlying this differ- 
ence remains to be elucidate d. 
Both the expression of GasQL and treatment with isoproter enol 
decrease d the p300 protein level, but isoproterenol was associated 
with a low expression of p300 mRNA, whereas GasQL caused high 
levels of p300 mRNA expression. It is not clear why GasQL expres- 
sion and isoproterenol treatment have different effects on p300 
mRNA expression. The level of p300 protein was analysed at 24 h
after transfection of GasQL and at 30 min after treatment with iso- 
proteren ol; thus, it is speculate d that the difference may be due to 
the different duration of activation of the signalling system. 
This study showed that cAMP signalling transiently decrease d
the levels of the p300 protein for more than 2 h post treatment. 
The decrease in levels of p300 could decrease the availability of 
p300 to the transcrip tional machinery and the acetylation reaction, 
thus causing changes in gene expression. Therefore, it will be nec- 
essary to analyse the changes in the expression of the p300 target 
genes to understand the signiﬁcance of the transient downregula- 
tion of the p300 protein level induced by cAMP signalling .
Based on these ﬁndings, it is concluded that the cAMP signalling 
system inhibits the accumulation of the p300 protein by promoting 
its ubiquitin /proteasome-dep endent degradation , which is medi- 
ated by Epac and p38, in lung cancer cells. This study describes a
novel mechanism through which the cAMP signalling system reg- 
ulates the level of the p300 protein, and perhaps consequent epige- 
netic regulation, in lung cancer cells. 
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